Verition Fund Management
SGMT icon

Verition Fund Management’s Sagimet Biosciences SGMT Stock Holding History

Verition Fund Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-154,670
Closed -$916K – 3394
2025
Q4 		$916K Buy
+154,670
New +$1.11M ﹤0.01% 2221
2024
Q3 		– Sell
-78,127
Closed -$267K – 3483
2024
Q2 		$267K Buy
78,127
+63,042
+418% +$289K ﹤0.01% 2415
2024
Q1 		$81.8K Buy
+15,085
New +$108K ﹤0.01% 2600

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Verition Fund Management's SGMT Position: Q1 2026 in Review

Verition Fund Management sold out of Sagimet Biosciences (SGMT) in Q1 2026, closing a stake of 154,670 shares — an estimated $916K sold.

Verition Fund Management first reported a position in SGMT in Q1 2024 and held it in 3 quarters. The position peaked at $916K in Q4 2025. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Verition Fund Management reported no remaining Sagimet Biosciences position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 154,670 Sagimet Biosciences shares in Q1 2026, an estimated $916K.
  • Verition Fund Management first reported a position in Sagimet Biosciences in Q1 2024 and held it in 3 quarters.
  • Verition Fund Management's Sagimet Biosciences position peaked at $916K in Q4 2025.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.